<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085055</url>
  </required_header>
  <id_info>
    <org_study_id>1469116</org_study_id>
    <nct_id>NCT04085055</nct_id>
  </id_info>
  <brief_title>Fine Needle Biopsy of Solid Pancreatic Mass Lesions</brief_title>
  <official_title>Randomized Trial Comparing Fine Needle Biopsy Needles and Different Techniques for Endoscopic-guided Fine Needle Biopsy of Solid Pancreatic Mass Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AdventHealth</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial to evaluate and directly compare the tissue quality, diagnostic
      sucess and safety profile of four different Fine Needle Biopsy needles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is currently the standard
      method for sampling solid pancreatic masses, with reported sensitivity for malignant cytology
      of 85-95%, specificity of 95-98% and diagnostic accuracy of 78-95%. Diagnostic failure of
      EUS-FNA can be due to inadequate targeting, inexperience of the endoscopist/pathologist, or
      necrotic or fibrotic tumors in which viable cells are difficult to obtain. The cellularity
      and architectural representation of the sample can also be determined by the needle used and
      its specific features. Recently, new needles known as &quot;fine needle biopsy (FNB)&quot; needles have
      become available that are specially designed to promote the collection of core tissue by
      unique designs of their needle tips. The advantages of FNB over FNA needles are that (a) the
      quality of tissue procured is superior: FNA needles yield cytology whereas FNB needles yield
      histology (b) molecular marker analysis can be performed more reliably on histology samples
      than cytology aspirates and (c) as histological tissue is greater in quantity than
      cytological aspirates, a quicker diagnosis with fewer passes can be established by histology
      than cytology.

      Four different types of FNB needles are currently available - reverse-bevel tip (EchoTip
      ProCore HD Ultrasound Biopsy Needle, Cook Medical, Bloomington, IN), Menghini-tip (EZ shot,
      Olympus America, Center Valley, PA), Franseen tip (Acquire, Boston Scientific Corporation,
      Natick, MA) and fork-tip (SharkCore, Medtronic Corporation/Covidien, Newton, MA) needles,
      each with unique tip designs to facilitate procurement of histological core tissue. Although
      we have previously compared in randomized trials the diagnostic yield of Franseen and
      fork-tip FNB needles and have shown the two needles to be equivalent, there are currently no
      randomized trials directly comparing all four FNB needle types. EUS-guided tissue acquisition
      can also be performed using different techniques, including the use of suction, no use of
      suction and the stylet retraction technique. There are currently no studies comparing these
      different tissue acquisition techniques using the different FNB needles and no study has
      demonstrated the best technique for FNB.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a randomized trial comparing four types of FNB needles and three sampling techniques. Patients will be randomized to one of the four different FNB needles. All patients will then undergo FNB using the specified needle and all three sampling techniques (one pass per technique using the assigned needle).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The patients, pathologists assessing the biopsy specimens and the research staff responsible for follow-up will be blinded to the FNB needle type utilized. Data will also be blinded for statistical analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of cellularity in biopsy sample</measure>
    <time_frame>3 days</time_frame>
    <description>Compare the degree of cellularity of the obtained tissue in the biopsy sample between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques. Cellularity is defined as the proportion of core tissue to total specimen area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic adequacy of the biopsy sample</measure>
    <time_frame>1 day</time_frame>
    <description>Documentation of the presence of adequate tissue material (pancreatic parenchyma and tumor if applicable) in the biopsy sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen bloodiness in biopsy sample</measure>
    <time_frame>1 day</time_frame>
    <description>Measured as the area of bloodiness in the biopsy sample, with calculation as a percentage in the microscopic field.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of crush artefact in biopsy sample</measure>
    <time_frame>1 day</time_frame>
    <description>Documenting the presence or absence of crush artefact in the biopsy sample. If present, it is measured as the area of artefact in biopsy sample, with calculation as a percentage in relation to the total sample area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical failure</measure>
    <time_frame>1 day</time_frame>
    <description>Measured as the inability to successfully perform the fine needle biopsy using the assigned needle, due to any needle dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 days, 30 days, and 6 months</time_frame>
    <description>The subject will be asked to report and medical records will be reviewed for any adverse events related to the procedure or the underlying disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic operating characteristics</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the diagnostic operating characteristics of the biopsy sample and detection of neoplasia (defined as sensitivity, specificity, negative predictive value, positive predictive value and accuracy) between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>22 Gauge FNB Needle - ProCore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 Gauge FNB Needle - Acquire</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 Gauge FNB Needle - SharkCore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 Gauge FNB needle - EZ Shot 3 Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Solid pancreatic mass lesion biopsy</intervention_name>
    <description>The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.</description>
    <arm_group_label>22 Gauge FNB Needle - Acquire</arm_group_label>
    <arm_group_label>22 Gauge FNB Needle - ProCore</arm_group_label>
    <arm_group_label>22 Gauge FNB Needle - SharkCore</arm_group_label>
    <arm_group_label>22 Gauge FNB needle - EZ Shot 3 Plus</arm_group_label>
    <other_name>biopsy, fine needle biopsy, fine needle aspiration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients referred for EUS-guided tissue acquisition of suspected or confirmed
             solid pancreatic mass lesions visualized on any radiological imaging

          2. Able and willing to provide written or verbal consent

          3. â‰¥ 18 years old

          4. Able to undergo conscious sedation for EUS procedure

        Exclusion Criteria:

          1. &lt;18 years old

          2. Unable to obtain informed consent from the patient

          3. Medically unfit for sedation

          4. Pregnant patients

          5. No pancreatic mass lesions visualized on EUS

          6. Irreversible coagulopathy as determined by platelet count &lt; 50,000/microL or
             International Normalized Ratio (INR) &gt; 1.5

          7. Unable to stop anti-platelet agents prior to the procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Varadarajulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AdventHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyam Varadarajulu, MD</last_name>
    <phone>407.303.2750</phone>
    <email>shyam.varadarajulu.md@adventhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Barron-Nelson</last_name>
    <phone>321.946.2747</phone>
    <email>robin.barron@flhosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ngamruengphong S, Li F, Zhou Y, Chak A, Cooper GS, Das A. EUS and survival in patients with pancreatic cancer: a population-based study. Gastrointest Endosc. 2010 Jul;72(1):78-83, 83.e1-2. doi: 10.1016/j.gie.2010.01.072.</citation>
    <PMID>20620274</PMID>
  </reference>
  <reference>
    <citation>Othman MO, Wallace MB. The role of endoscopic ultrasonography in the diagnosis and management of pancreatic cancer. Gastroenterol Clin North Am. 2012 Mar;41(1):179-88. doi: 10.1016/j.gtc.2011.12.014. Epub 2012 Jan 16. Review.</citation>
    <PMID>22341257</PMID>
  </reference>
  <reference>
    <citation>Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012 Feb;75(2):319-31. doi: 10.1016/j.gie.2011.08.049.</citation>
    <PMID>22248600</PMID>
  </reference>
  <reference>
    <citation>Varadarajulu S, Fraig M, Schmulewitz N, Roberts S, Wildi S, Hawes RH, Hoffman BJ, Wallace MB. Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy. 2004 May;36(5):397-401.</citation>
    <PMID>15100946</PMID>
  </reference>
  <reference>
    <citation>Bang JY, Hawes R, Varadarajulu S. A meta-analysis comparing ProCore and standard fine-needle aspiration needles for endoscopic ultrasound-guided tissue acquisition. Endoscopy. 2016 Apr;48(4):339-49. doi: 10.1055/s-0034-1393354. Epub 2015 Nov 12. Review.</citation>
    <PMID>26561917</PMID>
  </reference>
  <reference>
    <citation>Bang JY, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. EUS-guided fine needle biopsy of pancreatic masses can yield true histology. Gut. 2018 Dec;67(12):2081-2084. doi: 10.1136/gutjnl-2017-315154. Epub 2017 Oct 7.</citation>
    <PMID>28988195</PMID>
  </reference>
  <reference>
    <citation>Bang JY, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. Randomized trial comparing the Franseen and Fork-tip needles for EUS-guided fine-needle biopsy sampling of solid pancreatic mass lesions. Gastrointest Endosc. 2018 Jun;87(6):1432-1438. doi: 10.1016/j.gie.2017.11.036. Epub 2018 Jan 3.</citation>
    <PMID>29305893</PMID>
  </reference>
  <reference>
    <citation>Lee KY, Cho HD, Hwangbo Y, Yang JK, Han SJ, Choi HJ, Lee YN, Cha SW, Moon JH, Cho YD, Park SH, Lee TH. Efficacy of 3 fine-needle biopsy techniques for suspected pancreatic malignancies in the absence of an on-site cytopathologist. Gastrointest Endosc. 2019 Apr;89(4):825-831.e1. doi: 10.1016/j.gie.2018.10.042. Epub 2018 Nov 4.</citation>
    <PMID>30403966</PMID>
  </reference>
  <reference>
    <citation>Saxena P, El Zein M, Stevens T, Abdelgelil A, Besharati S, Messallam A, Kumbhari V, Azola A, Brainard J, Shin EJ, Lennon AM, Canto MI, Singh VK, Khashab MA. Stylet slow-pull versus standard suction for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic lesions: a multicenter randomized trial. Endoscopy. 2018 May;50(5):497-504. doi: 10.1055/s-0043-122381. Epub 2017 Dec 22.</citation>
    <PMID>29272906</PMID>
  </reference>
  <reference>
    <citation>Nakai Y, Isayama H, Chang KJ, Yamamoto N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Kawakubo K, Kogure H, Sasaki T, Hirano K, Tanaka M, Tada M, Fukayama M, Koike K. Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci. 2014 Jul;59(7):1578-85. doi: 10.1007/s10620-013-3019-9. Epub 2014 Jan 16.</citation>
    <PMID>24429514</PMID>
  </reference>
  <reference>
    <citation>Chow, S.C.; Shao, J.; Wang, H. 2008. Sample Size Calculations in Clinical Research, 2nd Edition. Chapman &amp; Hall/CRC. Boca Raton, FL. Pages 99-100.</citation>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic mass, pancreatic solid mass, pancreatic lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

